NDA 207318 · Acadia Pharms INC
Nuplazid
Pimavanserin Tartrate · Oral
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 29, 2016
Approved uses
4
Original approval plus efficacy supplements
Registered trials
45
15 Phase 3, 10 recruiting
FAERS reports
57,532
29,715 serious, 14,647 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning . Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease. ( 5.1 )
What it is approved for
From the label in effect Jun 18, 2026.
NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] . NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ( 1 )
Mechanism: The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with PDP is unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 27, 2026 Supplement 16 · Efficacy · priority review LetterLabel
- Sep 15, 2023 Supplement 12 · Efficacy LetterLabel
- Jun 28, 2018 Supplement 3 · Efficacy LetterLabel
- Apr 29, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelSummary ReviewLetter
2 products under this application
- NUPLAZID · PIMAVANSERIN TARTRATE EQ 17MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- NUPLAZID · PIMAVANSERIN TARTRATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pimavanserin" as an intervention, any sponsor and status, largest first.
- Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaPivotal-lookingTerminated
ACADIA Pharmaceuticals Inc.Industry
NCT03121586 · 995 participants · Start Jan 2017 · Primary completion Apr 30, 2024
Drug: Pimavanserin · For: Schizophrenia
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 161 sites in all
- A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseasePivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT03575052 · 784 participants · Start May 21, 2018 · Primary completion May 6, 2022
Drug: Pimavanserin; Placebo · For: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Sites: Gilbert, Arizona; Costa Mesa, California; Santa Ana, California · 104 sites in all
- Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseasePivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT03623321 · 595 participants · Start Jul 17, 2018 · Primary completion May 5, 2023
Drug: Pimavanserin · For: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Sites: Gilbert, Arizona; Costa Mesa, California; Santa Ana, California · 88 sites in all
- A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisPivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT00550238 · 459 participants · Start Jul 2007 · Primary completion May 30, 2018
Drug: Pimavanserin tartrate (ACP-103) · For: Parkinson's Disease Psychosis
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 135 sites in all
- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaPivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT04531982 · 454 participants · Start Aug 5, 2020 · Primary completion Jan 25, 2024
Drug: Pimavanserin; Placebo · For: Schizophrenia
Sites: Buenos Aires, Argentina; Ciudad Autonoma Buenos Aires, Argentina; Córdoba, Argentina · 102 sites in all
- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)Pivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT02970305 · 403 participants · Start Nov 4, 2016 · Primary completion Oct 16, 2019
Drug: Pimavanserin; Placebo · For: Schizophrenia
Sites: Phoenix, Arizona; Rogers, Arkansas; Bellflower, California · 101 sites in all
- Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and RisperidonePivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT00361166 · 400 participants · Start Aug 2005
Drug: ACP-103 · For: Schizophrenia
Sites: Cerritos, California; Garden Grove, California; Glendale, California · 17 sites in all
- Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)Pivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT02970292 · 396 participants · Start Oct 26, 2016 · Primary completion May 28, 2019
Drug: Pimavanserin; Placebo · For: Schizophrenia
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 105 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hallucination13,278
- death11,261
- drug ineffective6,630
- confusional state4,448
- product dose omission issue4,364
- fall4,197
- delusion2,852
- condition aggravated2,605
- hallucination, visual2,413
- parkinson^s disease2,350
- gait disturbance2,289
- urinary tract infection1,923
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1,269 |
| 2017 | 4,548 |
| 2018 | 4,467 |
| 2019 | 2,606 |
| 2020 | 5,917 |
| 2021 | 4,703 |
| 2022 | 4,300 |
| 2023 | 4,501 |
| 2024 | 7,184 |
| 2025 | 10,493 |
| 2026 | 7,542 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nuplazid (Pimavanserin Tartrate)
2024 spending
$658M
Beneficiaries
17,122
143,328 claims
Per beneficiary
$38,420
$165.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $416,044,322 |
| 2021 | $470,863,042 |
| 2022 | $528,932,689 |
| 2023 | $595,675,170 |
| 2024 | $657,826,493 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN, Cummings JL, Soto-Martin ME, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J, Isaacson S, Mills R, et al. · Lancet 2014 · Clinical Trial, Phase III, Multicenter Study
- How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
Agnieszka W, Pawe P, Magorzata K · Curr Neuropharmacol 2022 · Systematic Review
- Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial.
Weintraub D, Espay AJ, Sharma VD, et al. · Parkinsonism Relat Disord 2024 · Randomized Controlled Trial, Multicenter Study
- New Antipsychotic Medications in the Last Decade.
Pahwa M, Sleem A, Elsayed OH, et al. · Curr Psychiatry Rep 2021 · Systematic Review
- Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis.
Srisurapanont M, Suradom C, Suttajit S, et al. · Gen Hosp Psychiatry 2024 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Acadia Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.